Use extra caution if you have cancer history, clotting disorders, cardiovascular disease, autoimmune conditions, or if you take anticoagulants, antiplatelet drugs, or immunomodulators
Benefits of Combining SGLT2 Inhibitors with GLP-1 Receptor Agonists on Cardiovascular Outcomes The summarized information indicates that the evidence from primary prevention studies is less robust than that derived from secondary prevention studies
(XLSX 41 kb) Additional file 3: (download XLSX Table S3: Functional classifications of identified proteins significantly expressed in leaves of tea plants exposed to the treatments T4/T3 for 7 days (4 C and 4 C + GABA for T3 and T4, respectively)
Kumarathurai P, Sajadieh A, Anholm C, Kristiansen OP, Haugaard SB, Nielsen OW
8 800 700 88 88 7 ~ 5 L- N20 560 , 247